Clinical trials: Myeloid Neoplasm
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Reduced Intensity Double Umbilical Cord Blood Transplantation
This trial will use two cord blood units for transplantation using a reduced intensity regimen rather than using intense doses of chemotherapy and radiation therapy.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01408563
- Testing
- Fludarabine, Melphalan, Total Body Radiation
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
The goal of this study is to determine whether post-transplant consolidation with azacitidine combined with donor lymphocyte infusion (DLI) is a safe and effective approach for the prevention of relapse in pediatric and young…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02458235
- Testing
- azacitidine, donor lymphocyte infusion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Acute Myeloid Leukemia, Neutropenia
Home Away From Home - Medical Outcomes
Treatment for pediatric acute myeloid leukemia (AML) involves intensive chemotherapy regimens that result in periods of profound neutropenia leaving patients susceptible to severe infectious complications.
- Conditions
- Acute Myeloid Leukemia, Neutropenia, Bacteremia
- Trial name
- Aim 1 (NCT02774850)
- Where
- 17 sites in United States
- Volunteers
- 610 people
- Sponsor
- Children's Hospital of Philadelphia
Leukemia, Myeloid, Chronic-Phase
Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response
The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response and major molecular response rate) is…
- Trial name
- MIM (NCT01827930)
- Testing
- Imatinib Mesylate 600 MG Oral Tablet, Imatinib Mesylate 400 MG Oral Tablet, Imatinib Mesylate
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Institut Bergonié
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an improvement in treatment-related mortality (TRM) rate at 6 months.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
- Trial name
- NCT00593554
- Testing
- Total Body Irradiation, Thiotepa, Fludarabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sherif S. Farag
Myeloid Leukemia, Chronic
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response
Imatinib mesylate is standard treatment of Chronic myeloid leukaemia, complete cytogenetic response is obtained in most of cases but molecular response concerned only a small part of the patients.
- Trial name
- AFR22 (NCT00210119)
- Testing
- Glivec
- Where
- 7 sites in France
- Volunteers
- 19 people
- Sponsor
- Institut Bergonié
Acute Myeloid Leukemia
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
The primary objective of this study is to determine whether low-dose cytarabine in combination with arsenic trioxide is more effective than low-dose cytarabine alone in achieving complete remission in elderly patients (≥60 years…
- Trial name
- NCT00513305
- Testing
- Arsenic trioxide, Low-dose cytarabine alone
- Where
- 12 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Cephalon
Primary Myelofibrosis, Secondary Myelofibrosis
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
This pilot clinical trial studies how well imetelstat sodium works in treating participants with primary or secondary myelofibrosis and other myeloid malignancies.
- Conditions
- Primary Myelofibrosis, Secondary Myelofibrosis, Myeloid Malignancies
- Trial name
- NCT01731951
- Testing
- Imetelstat
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Geron Corporation
Leukemia
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
RATIONALE: Giving intensity modulated radiation therapy (IMRT) and chemotherapy, such as etoposide and cyclophosphamide, before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00576979
- Testing
- cyclophosphamide, etoposide, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- City of Hope Medical Center
Leukemia
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
The goal of Phase I of this clinical research study is find the highest tolerable dose of clofarabine that can be given with decitabine, idarubicin, and cytarabine to patients with acute leukemia.
- Trial name
- NCT01794702
- Testing
- Decitabine, Idarubicin, Cytarabine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia
This was an open-label pilot study that evaluated the safety and preliminary evidence of a therapeutic effect of dociparstat in conjunction with standard induction and consolidation therapy for acute myeloid leukemia (AML).
- Trial name
- PGX-AML (NCT02056782)
- Testing
- Dociparstat sodium
- Volunteers
- 12 people
- Sponsor
- Jazz Pharmaceuticals
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
This is a continuation of a pilot study which is now regarded as a phase II trial with a plan to enroll an additional 40 patients (20 related and 20 unrelated donor transplants) with hematological malignancy assessing the safety…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00571662
- Testing
- Pentostatin, Total-body irradiation (TBI), Cyclosporine A (CsA)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of Nebraska
Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
This pilot phase II trial studies how well high dose cyclophosphamide, tacrolimus, and mycophenolate mofetil work in preventing graft versus host disease in patients with hematological malignancies undergoing myeloablative or…
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03128359
- Testing
- Busulfan, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia
Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)
The purpose of this study is to assess the safety of OCV-501 in patients with AML who completed the Study 311-10-001 and were judged that there was no relapse by any inspections in the end of the study.
- Trial name
- NCT01475370
- Testing
- OCV-501
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT03399773
- Testing
- Dilanubicel, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Phase Chronic Myeloid Leukemia
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
The purpose of this study is to test the hypothesis that patients with CML who have not achieved optimal response after 3 months of treatment with imatinib will have a better response by switching to dasatinib compared to staying…
- Trial name
- DASCERN (NCT01593254)
- Testing
- Imatinib, Dasatinib
- Where
- 101 sites in United States, Argentina and 13 more
- Volunteers
- 262 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Acute Myeloid Leukemia
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
This phase II trial tests how well decitabine and cedazuridine (DEC-C) works in combination with venetoclax in treating acute myeloid leukemia (AML) in patients whose AML has come back after a period of improvement (relapse)…
- Trial name
- NCT05799079
- Testing
- Venetoclax, Decitabine, Cedazuridine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sanjay Mohan
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
This randomized phase II trial studies how well cytarabine with or without SCH 900776 works in treating adult patients with relapsed acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Trial name
- NCT01870596
- Testing
- Cytarabine, CHK1 Inhibitor SCH 900776, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
This was a parallel, Phase 1/Phase 2, randomized, open label, multi-cohort, multi-center study assessing the safety, tolerability and preliminary efficacy of SAR443579 with different agents for treatment in adolescent and/or…
- Trial name
- NCT06508489
- Testing
- SAR443579, venetoclax, azacitidine
- Where
- 7 sites in United States, Australia
- Volunteers
- 7 people
- Sponsor
- Sanofi
Chronic Myeloid Leukemia
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
This is an open-label, continuous daily dosing, two-part safety and efficacy study of SKI-606 (bosutinib) in Philadelphia chromosome positive leukemias (Ph+).
- Trial name
- NCT00261846
- Testing
- Bosutinib
- Where
- 111 sites in United States, Argentina and 25 more
- Volunteers
- 571 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.